Filing Flows

Filing Flows › Companies › Tandem Diabetes Care › Cash flow

Tandem Diabetes Care cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$5.5M in Q3 2026 · −$36.3M over twelve months

Operating cash flow−$819K
Capital spending−$4.7M
Free cash flow−$5.5M
Cash conversion cycle107 days

Analysis

In Q3 2026, Tandem Diabetes Care generated −$819K of operating cash flow and spent $4.7M on capital projects, leaving free cash flow of −$5.5M. That is $9.7M less than in Q3 2025 ($4.2M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$14.6M; the largest uses were other investing ($258M), other financing ($60.0M), capital spending ($21.7M); besides operations, cash came from net borrowing (+) / repaid (−) ($332M); the cash balance fell by $19.1M.

Operating cash flow was −$819K against net income of −$7.1M. The largest differences: receivables −$21.5M, stock-based pay +$15.9M, employee-related liabilities +$11.0M.

Its cash conversion cycle was 107 days (receivables 55 + inventory 104 − payables 52).

Free cash flow

Tandem Diabetes Care: free cash flow by quarterTandem Diabetes Care: free cash flow by quarter$7.6MQ4 2024−$21.2MQ1 2025−$15.7MQ2 2025$4.2MQ3 2025$3.1MQ4 2025$4.8MQ1 2026−$38.7MQ2 2026−$5.5MQ3 2026
Operating cash flow less capital spending.
Tandem Diabetes Care: operating cash flow against capital spendingTandem Diabetes Care: operating cash flow against capital spendingOperating cash flowCapital spending$10.7M$3.1MQ4 2024−$18.3M$3.0MQ1 2025−$9.5M$6.2MQ2 2025$8.3M$4.1MQ3 2025$9.8M$6.7MQ4 2025$11.1M$6.3MQ1 2026−$34.6M$4.0MQ2 2026−$819K$4.7MQ3 2026
Latest (Q3 2026): Operating cash flow −$819K, Capital spending $4.7M.

Capital allocation, year by year

Tandem Diabetes Care: where the cash came from (up) and went (down), by fiscal yearTandem Diabetes Care: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingBuybacksFY2021: Operating cash flow $111MFY2021: Shares issued $51.3MFY2021: Capital spending −$14.2M$163MFY2021FY2022: Operating cash flow $50.5MFY2022: Shares issued $17.5MFY2022: Capital spending −$34.1M$67.9MFY2022FY2023: Operating cash flow −$31.8MFY2023: Shares issued $4.2MFY2023: Capital spending −$26.8M$4.2MFY2023FY2024: Operating cash flow $24.2MFY2024: Net borrowing $60.7MFY2024: Shares issued −$6.7MFY2024: Capital spending −$19.2MFY2024: Buybacks −$30.0M$85.0MFY2024FY2025: Operating cash flow −$9.7MFY2025: Capital spending −$19.9MFY2025
Over these 5 years operating cash flow totalled $145M; the largest uses were capital spending ($114M) and operating cash flow ($41.5M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$443M
Debt$603M
Net debt$160M
Cash runwaymore than 10 years

Tandem Diabetes Care is burning cash: its operations consume cash, a free cash flow of −$36.3M a year at the current rate against $443M of cash and investments: a runway of more than ten years at that rate before any new financing.

Where the cash came from and went

Tandem Diabetes Care: sources (+) and uses (−) of cash, Q3 2026Tandem Diabetes Care: sources (+) and uses (−) of cash, Q3 2026Other investing$22.7MCash drawn (+) / kept (−)−$10.0MCapital spending−$4.7MNet borrowing (+) / repaid (−)−$4.5MOther financing−$2.5MOperating cash flow−$819KExchange rates−$111K
Tandem Diabetes Care: sources (+) and uses (−) of cash, TTM to Q3 2026Tandem Diabetes Care: sources (+) and uses (−) of cash, TTM to Q3 2026Net borrowing (+) / repaid (−)$332MOther investing−$258MOther financing−$60.0MCapital spending−$21.7MCash drawn (+) / kept (−)$19.1MOperating cash flow−$14.6MExchange rates$3.4M

From profit to cash

Tandem Diabetes Care: net income to operating cash flow, Q3 2026Tandem Diabetes Care: net income to operating cash flow, Q3 2026Net income−$7.1MDepreciation & amortization$4.5MStock-based pay$15.9MReceivables−$21.5MInventory−$10.9MPayables$2.6MEmployee-related liabilities$11.0MDeferred revenue$1.8MPrepaid and other assets−$807KOther liabilities−$2.0MOperating cash flow−$819K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20265510452107
Q2 20265410851111
Q1 20265610444116
Q4 20254610035110
Q3 20254711241118
Q2 20254811246115
Q1 20254611341119
Q4 20243611134113

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$819K−$4.7M−$4.5M—−$10.0M−$5.5M
Q2 2026−$34.6M−$4.0M——$117M−$38.7M
Q1 2026$11.1M−$6.3M$291M—−$88.7M$4.8M
Q4 2025$9.8M−$6.7M$40.8M—$1.3M$3.1M
Q3 2025$8.3M−$4.1M——−$27.8M$4.2M
Q2 2025−$9.5M−$6.2M——−$10.5M−$15.7M
Q1 2025−$18.3M−$3.0M——$15.7M−$21.2M
Q4 2024$10.7M−$3.1M—$2.3M−$20.2M$7.6M

Tandem Diabetes Care: income statement and cash flow

Tandem Diabetes Care, Q3 2026: revenue $284M (+14% year over year), operating margin -0.8%. The chart follows the revenue to costs, profit and cash.

Tandem Diabetes Care: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.